Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Dracen Pharmaceuticals
company
About
Dracen Pharmaceuticals is a developer of novel glutamine antagonists created to deliver improved outcomes for cancer patients.
- 251 - 500
Highlights
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $40M
- Industries
- Health Care,Pharmaceutical
- Founded date
- Jan 1, 2016
- Number Of Employee
- 251 - 500
- Operating Status
- Active
Dracen Pharmaceuticals is a developer of novel glutamine antagonists created to deliver improved outcomes for cancer patients and potentially extend the benefits of immuno-oncology therapies. The company develops novel glutamine antagonists with direct anti-tumor apoptotoc properties as well as endogenous anti-tumor immune modulatory mechanisms which increases the number of responders to anti-cancer therapy and extend survival for anti-tumor responses in areas currently evading immuno-oncology approaches.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$40M
Dracen Pharmaceuticals has raised a total of
$40M
in funding over 2 rounds. Their latest funding was raised on
Mar 22, 2018 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 22, 2018 | Series A | $40M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Dracen Pharmaceuticals is funded by 1 investors.
i&i Prague
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
